Shaping the future Of Medicinal Cannabis
We believe Australian patients have the right to access high quality, cost effective, cannabinoid medicines. Quality control is our no.1 priority.
Ensuring ‘Good Manufacturing Practices’, we are committed to supplying our clients with a consistent & reliable source of high-quality medicinal cannabis.
AusCann brings together a strong team with relevant & complementary skill-sets, experience and networks.
For over 12,000 years, the Cannabis plant has provided humankind with food, fibre, and medicine.
with an increasing number of jurisdictions legislating in favour of the use of Cannabis for medical purposes.
such as treatment of chronic pain, neuropathic pain, as anti-emetics in the treatment of chemotherapy-induced nausea and vomiting and for improving patient-reported multiple sclerosis spasticity.
and significant first hand evidence are demonstrating the medical benefits of this ancient traditional medicine.
AusCann releases low-dose form capsule to enable customised dosing solutions. View the ASX Announcement here: bit.ly/38NGpLu
AusCann accelerates commercialisation path with capsules released for clinical evaluation during December Quarter. You can view our Quarterly Activities Report here: bit.ly/2uO24UL
Big milestone announced today with the release of AusCann's hard-shell capsules for clinical evaluation and commence a fast track path to market bit.ly/36MKnTu
@TGAgovau has released the technical guide to GMP for medicinal cannabis bit.ly/2P8yX6w. This underpins AusCann’s approach to manufacturing where validation of its Pharmaceutical Quality System has been completed ahead of the release of products for clinical trials.
Announcing today a packaging agreement with @aspenpharma for our medicinal cannabis pharmaceutical products
We are delighted by the appointment of cannabinoid R&D and clinical trial expert, Dr. Marcel Bonn-Miller, to the AusCann Board as Non-Executive Director bit.ly/2lzbX4l
AusCann continues to strengthen strategic partnerships during June Quarter. You can view our June Quarterly Activities Report here: bit.ly/2GDOAy0
AusCann signs new supply agreement with TasAlk for the supply of cannabis resin to be used for AusCann's cannabinoids-based pharmaceutical product line bit.ly/2LsxGWw